Navigation Links
Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
Date:9/27/2007

Barcelona, Spain: Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists.

The study, presented today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, found that the drug more than doubled the average disease-free survival from 4.9 months to 11.4 months.

We believe that a median disease-free survival of 11.4 months is an outstanding result. It means an improvement, or reduction in the risk of recurrence, of 41 percent, said the studys lead researcher, Dr Tomoo Kosuge, deputy director of the National Cancer Center Hospital in Tokyo, Japan. That is difficult to achieve in patients with pancreatic cancer.

Pancreatic cancer has among the poorest prognoses. Most often, it has already spread by the time it is diagnosed, but in about 20 percent of patients, surgery is a viable option. However, even if it can be operated on, the cancer normally recurs and more than half of patients die within 20 months of their diagnosis. Only around 20 percent of them are still alive five years after being diagnosed.

Chemotherapy with gemcitabine is the standard treatment for advanced pancreatic cancer that cannot be operated on. As for resectable pancreatic cancer, researchers are investigating whether chemotherapy or chemoradiation might help. However, there is no universally accepted adjuvant treatment for patients whose pancreas can be removed, so mere observation after surgery is still the widely accepted approach.

In the latest study, 118 patients whose pancreatic cancer could be cut out were either given gemcitabine chemotherapy after surgery or closely monitored by doctors. Both groups were followed for more than 20 months.

The disease recurred in 72 percent of the patients getting gemcitabine, compared with 85 percent of those on observation. The overall survival, meaning survival regardless of whether the disease progressed, was better in the gemcitabine group, but those results were not statistically significant.

In the results of our study, the lack of a significant difference in the overall survival means the observation approach was not altogether negated. We therefore propose that chemotherapy with gemcitabine, as well as observation, now be considered as optimal treatment for patients with operable pancreatic cancer, Kosuge said.

The Japanese study bolsters the findings of a German study published earlier this year that similarly found gemcitabine delays progression of the disease after surgery.


'/>"/>

Contact: Emma Ross
rosswrite@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. New Method Of Delivering Chemotherapy
8. The Benefits Of Chemotherapy For Women With Ovarian Cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Using herbal remedies with chemotherapy may not be a good idea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
Breaking Medicine Technology: